Disease Detection Simplified
The most transformative solutions make things easier, faster, or more economical. Darwin’s point-of-care platform delivers on all three—offering a streamlined, effective tool for earlier detection and smarter disease management.
Welcome to our Lab
Darwin's breakthrough diagnostic device leverages a unique biomarker panel to detect the immune signature indicative of acute-phase infections.
Completely self-contained, it works independent of laboratories and even power sources. That means point-of-care can be anywhere.
Our non-invasive test delivers fast, accurate results and a critical advantage in clinical and operational settings.
Advanced Science Intuitive Experience
• Saliva Collection
• Swab Insertion
• Saliva Processing
• Heater Activation
• RNA Amplification
• Results Presentation
Select Traits
Non-invasive
Uses saliva instead of blood for easier, patient-friendly sampling.
Broad Infection Detection
Identifies an immune response indicative of infection, regardless of pathogen type.
Scalable Platform
Adaptable for detecting nucleic acids relevant to various disease spaces.
Military Precision
Our technology originated from military-funded research aimed at developing rapid, field-deployable diagnostic solutions.
Historically, some of the most impactful medical advancements, such as trauma care techniques and prosthetic innovations, began in military settings before revolutionizing civilian healthcare. Building on this legacy, our platform offers a game-changing solution for both military and commercial markets.
The Power of Early Sepsis Detection
Sepsis is a leading cause of mortality in hospitals worldwide, with delayed diagnosis often resulting in severe complications or death.
Every hour that a septic patient goes without treatment increases the risk of death by 8%.
Our technology addresses this critical challenge by providing early, reliable sepsis detection. It’s faster, more accessible and considerably less expensive than comparable tests.
This enables timely interventions that can save lives and reduce long-term complications.
Versatile Platform–Built for Strategic Partnerships
- Current Focus
- Near-Term Growth
- Future Potential
Explore our vision by phase:
Our diagnostic platform is designed to serve as a foundation for a wide range of applications. Companies developing POC molecular diagnostics in human and animal health can leverage our technology to develop targeted diagnostic solutions tailored to their respective markets.
From Sepsis to Ebola, Darwin technology is proving effective. We are at various stages of cinical development and are actively pursuing strategic partnerships.
Backstory
The following challenge from the US Government was the inspiration that launched Darwin Biosciences:
Limit disease outbreaks with an easy-to-use device that detects the presence of all known and unknown pathogens.
The company was founded in March of 2020, and pivoted directly into COVID-19 detection. Darwin's saliva-based solution was proven comparable to other tests and used thousands of times.
In the years since, Darwin has completed milestone after milestone and fulfilled our original mission. $17 million of investment has yielded a one-of-a-kind device that is trancending expectations.
Leadership
-
Nick Meyerson, Ph.D.
CEO and CO-FOUNDER
Evolution | Virology | Immunology
-
Sara Sawyer, Ph.D.
DIRECTOR and CO-FOUNDER
Professor, CU Boulder
-
Amy Emerman, Ph.D.
DIRECTOR PRODUCT DEVELOPMENT
Device Strategy | RNA
-
Claire Alexander, B.S.N., M.B.A.
VP CLINICAL AFFAIRS and OPERATIONS
Study Design and Execution
Advisors
-
Byron Hewett, M.B.A.
DIRECTOR
CEO, General Inception
-
Peter Bryant-Greenwood, M.D.
MEDICAL ADVISOR
CMO, Brazos Neuroscience
-
Micah McClain, M.D., Ph.D.
MEDICAL ADVISOR
Associate Professor, Duke University
-
Daniel Larremore, Ph.D.
SCIENTIFIC ADVISOR
Associate Professor, CU Boulder
Catalysts